Doctor of Oncology, Peking University Health Science Center, Associate Chief Physician, currently serving as Deputy Director of the Second Ward, Department of Thoracic Medical Oncology, Peking University Cancer Hospital. Specialties: He has long‑term dedication to medical treatment and clinical teaching of thoracic tumors, focusing on comprehensive treatment strategies for primary lung cancer, covering chemotherapy, targeted therapy, immunotherapy and other fields. As a core member of the department’s clinical and research team, he has been deeply involved in the application and implementation of multiple ongoing research projects. He has participated in more than 150 clinical trials of new drugs including immunotherapy, accumulated over one thousand clinical cases of lung cancer treated with targeted and immunotherapies, and possesses extensive clinical practice experience and solid research capabilities. From August 2017 to July 2018, he worked as a visiting scholar at Fred Hutchinson Cancer Research Center in the United States for one year. His research focused on the cutting‑edge field of epigenetics, with an emphasis on exploring the inhibitory effect and mechanism of PRMT‑5 inhibitors on tumor proliferation in small‑cell lung cancer cell lines and PDX mouse models.

Long-term dedication to the medical treatment and clinical teaching of thoracic tumors, with a focus on comprehensive treatment strategies for primary lung cancer, covering areas such as chemotherapy, targeted therapy, and immunotherapy.